Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Canadian Securities Exchange
  5. InnoCan Pharma Corporation
  6. Company
    INNO   CA45783P1027

INNOCAN PHARMA CORPORATION

(INNO)
Delayed Canadian Securities Exchange  -  03:20:19 2023-06-05 pm EDT
0.2600 CAD   -7.14%
05/31Innocan Pharma Corp Brief: Citing US$1.3 Million Increase in Revenues Compared to Q1 2022
MT
05/31Innocan Pharma Reports Q1 2023 Results including US$1.3M Increase in Revenues Compared to Q1 2022
AQ
05/30InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
Business Summary
Logo InnoCan Pharma Corporation
Innocan Pharma Corporation is an Israel-based pharmaceutical company active in the medical cannabis industry. It operates through three distinct operating segments: Research, Development, Marketing, Distribution and sales of InnoCan-branded over the counter (OTC) pharmaceutical products; Research and Development of Non-pharmaceutical products for third parties and Research and Development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales. The Company is developing an OTC topical treatments product line and new platform to facilitate the targeted controlled administration of cannabinoids via injection.
Sales per Business
20212022Delta
Cannabidiol-integrated Pharmaceuticals0.25100%3.33100% +1255.72%
CAD in Million
Sales per region
2022
United States3.1594.5%
United Kingdom0.113.2%
Rest of the World0.082.3%
CAD in Million
Managers
Name Title Age Since
Iris Or Gabi Bincovich Chief Executive Officer & Director - 2018
Nelson Halpern Chief Financial Officer - -
Nir Avram Chief Technology Officer 69 -
Roni Kamhi Chief Operating Officer - 2022
Eyal Flom Secretary & Director 57 2020
Yoram Nathan Drucker Director & Vice President-Business Development 57 2018
Members of the board
Name Title Age Since
Ron Abraham Mayron Executive Chairman 59 2019
Iris Or Gabi Bincovich Chief Executive Officer & Director - 2018
Yoram Nathan Drucker Director & Vice President-Business Development 57 2018
Ralph C. L. Bossino Director - 2019
Joshua Aaron Lintern Director 35 2019
Eyal Flom Secretary & Director 57 2020
Peter David Bloch Director 62 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 249,728,111 177,835,968 71.2% 0 0.0% 71.2%
Shareholders
NameEquities%
Solsken Ltd. 48,595,875 19.6%
Yoram Druker 12,201,000 4.91%
Ron Abraham Mayron 5,160,000 2.08%
Iris Or Gabi Bincovich 2,859,750 1.15%
Eyal Flom 1,837,500 0.74%
PP-Asset Management GmbH 528,000 0.21%
Nelson Halpern 300,000 0.12%
Peter David Bloch 0 -
Ralph C. L. Bossino 0 -
Nir Avram 0 -
Company contact information
InnoCan Pharma Corp.
10 Hamenofim Street
Herzliya, Tel Aviv 4672561

Web : http://www.innocanpharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of InnoCan Pharma Corporation
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
INNOCAN PHARMA CORPORATION30.23%52
JOHNSON & JOHNSON-11.14%439 119
ELI LILLY AND COMPANY20.91%419 892
NOVO NORDISK A/S15.25%349 309
MERCK & CO., INC.1.42%285 512
ROCHE HOLDING AG0.79%260 350
ABBVIE INC.-15.31%241 478
ASTRAZENECA PLC4.72%227 170
PFIZER, INC.-25.14%216 554
NOVARTIS AG6.91%206 648
BRISTOL-MYERS SQUIBB COMPANY-8.74%137 942
SANOFI5.72%127 245
AMGEN INC.-16.97%116 521
GILEAD SCIENCES, INC.-9.27%97 156
GSK PLC-4.87%69 143
DAIICHI SANKYO CO., LTD.10.85%64 660
BAYER AG8.87%55 444
TAKEDA PHARMACEUTICAL COMPANY LIMITED8.68%49 721
CHUGAI PHARMACEUTICAL CO., LTD15.23%45 705
JIANGSU HENGRUI MEDICINE CO., LTD.20.69%41 458
HALEON PLC-0.05%37 698
Stock markets for all
100% Free Registration
fermer